Here we go again. With Aduhelm largely sidelined, Biogen and Eisai are hoping for a better fortunes with their next Alzheimer's disease therapy lecanemab, which is now fully filed with the FDA.
After months of debate about the validity of its phase 3 clinical trials for Alzheimer's therapy Aduhelm, Biogen has published the results in a peer-review journal, allowing physicians to look at ...
To sign up for Becker's Payer Issues E-Newsletter or any of our other E-Newsletters, click here. If you are experiencing difficulty receiving our newsletters, you may ...